Swee Lay Thein

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7102200/publications.pdf

Version: 2024-02-01

132 papers	9,926 citations	81434 41 h-index	42259 96 g-index
137 all docs	137 docs citations	137 times ranked	9424 citing authors

#	Article	IF	Citations
1	Evaluation of Hepatic Iron Overload Using a Contemporary 0.<scp>55â€‰T MRI</scp> System. Journal of Magnetic Resonance Imaging, 2022, 55, 1855-1863.	1.9	4
2	Genetic variants of PKLR are associated with acute pain in sickle cell disease. Blood Advances, 2022, 6, 3535-3540.	2.5	6
3	Mitapivat increases ATP and decreases oxidative stress and erythrocyte mitochondria retention in a SCD mouse model. Blood Cells, Molecules, and Diseases, 2022, 95, 102660.	0.6	9
4	A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease. Blood, 2022, 140, 2053-2062.	0.6	34
5	Revisiting anemia in sickle cell disease and finding the balance with therapeutic approaches. Blood, 2022, 139, 3030-3039.	0.6	8
6	Cardiovascular complications of sickle cell disease. Trends in Cardiovascular Medicine, 2021, 31, 187-193.	2.3	32
7	Dietary iron restriction improves markers of disease severity in murine sickle cell anemia. Blood, 2021, 137, 1553-1555.	0.6	14
8	A phenotypic risk score for predicting mortality in sickle cell disease. British Journal of Haematology, 2021, 192, 932-941.	1.2	9
9	An Imaging Flow Cytometry Method to Measure Citrullination of H4 Histone as a Read-out for Neutrophil Extracellular Traps Formation. Bio-protocol, 2021, 11, e3927.	0.2	3
10	Targeting ZNF410 as a potential Î²-hemoglobinopathy therapy. Nature Genetics, 2021, 53, 589-590.	9.4	2
11	NLRP3 inflammasome and bruton tyrosine kinase inhibition interferes with upregulated platelet aggregation and inÂvitro thrombus formation in sickle cell mice. Biochemical and Biophysical Research Communications, 2021, 555, 196-201.	1.0	12
12	Research in Sickle Cell Disease: From Bedside to Bench to Bedside. HemaSphere, 2021, 5, e584.	1.2	16
13	Circulating mitochondrial DNA is a proinflammatory DAMP in sickle cell disease. Blood, 2021, 137, 3116-3126.	0.6	51
14	Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin. Blood, 2021, 138, 1172-1181.	0.6	52
15	Pro-inflammatory cytokines associate with NETosis during sickle cell vaso-occlusive crises. Cytokine, 2020, 127, 154933.	1.4	33
16	Detection and Quantification of Histone H4 Citrullination in Early NETosis With Image Flow Cytometry Version 4. Frontiers in Immunology, 2020, 11, 1335.	2.2	8
17	Allosteric control of hemoglobin S fiber formation by oxygen and its relation to the pathophysiology of sickle cell disease. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 15018-15027.	3.3	26
18	Treating sickle cell anemia. Science, 2020, 367, 1198-1199.	6.0	44

#	Article	IF	Citations
19	Hemolytic transfusion reactions in sickle cell disease: underappreciated and potentially fatal. Haematologica, 2020, 105, 539-544.	1.7	44
20	Whole genome sequence-based haplotypes reveal a single origin of the 1393 bp HBB deletion. Journal of Medical Genetics, 2020, 57, 567-570.	1.5	5
21	American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Advances, 2020, 4, 327-355.	2.5	241
22	COVID-19 and sickle cell disease. Haematologica, 2020, 105, 2501-2504.	1.7	30
23	A Growing Population of Older Adults with Sickle Cell Disease. Clinics in Geriatric Medicine, 2019, 35, 349-367.	1.0	5
24	The carrier state for sickle cell disease is not completely harmless. Haematologica, 2019, 104, 1106-1111.	1.7	38
25	Neutrophils remain detrimentally active in hydroxyurea-treated patients with sickle cell disease. PLoS ONE, 2019, 14, e0226583.	1.1	16
26	Voxelotor treatment of a patient with sickle cell disease and very severe anemia. American Journal of Hematology, 2019, 94, E88-E90.	2.0	9
27	Genetic Modifiers of Fetal Haemoglobin in Sickle Cell Disease. Molecular Diagnosis and Therapy, 2019, 23, 235-244.	1.6	32
28	Pain and opioid use after reversal of sickle cell disease following <scp>HLA</scp>â€matched sibling haematopoietic stem cell transplant. British Journal of Haematology, 2019, 184, 690-693.	1.2	37
29	Optimal disease management and health monitoring in adults with sickle cell disease. Hematology American Society of Hematology Education Program, 2019, 2019, 505-512.	0.9	7
30	Beta thalassaemia intermedia due to coâ€inheritance of three unique alpha globin cluster duplications characterised by next generation sequencing analysis. British Journal of Haematology, 2018, 180, 160-164.	1.2	19
31	Sickle Cell Anemia and Its Phenotypes. Annual Review of Genomics and Human Genetics, 2018, 19, 113-147.	2.5	66
32	Platelets at the crossroads of thrombosis, inflammation and haemolysis. British Journal of Haematology, 2018, 180, 761-767.	1.2	28
33	MYB â€“ A regulatory factor in hematopoiesis. Gene, 2018, 665, 6-17.	1.0	48
34	Switching from fetal to adult hemoglobin. Nature Genetics, 2018, 50, 478-480.	9.4	23
35	Molecular basis of Î² thalassemia and potential therapeutic targets. Blood Cells, Molecules, and Diseases, 2018, 70, 54-65.	0.6	138
36	Heterogeneity of respiratory disease in children and young adults with sickle cell disease. Thorax, 2018, 73, 575-577.	2.7	12

#	Article	IF	Citations
37	How I treat the older adult with sickle cell disease. Blood, 2018, 132, 1750-1760.	0.6	31
38	g(HbF): a genetic model of fetal hemoglobin in sickle cell disease. Blood Advances, 2018, 2, 235-239.	2.5	33
39	The platelet NLRP3 inflammasome is upregulated in sickle cell disease via HMGB1/TLR4 and Bruton tyrosine kinase. Blood Advances, 2018, 2, 2672-2680.	2.5	56
40	Sickle cell diseaseâ€"Unanswered questions and future directions in therapy. Seminars in Hematology, 2018, 55, 51-52.	1.8	2
41	A survey of genetic fetal-haemoglobin modifiers in Nigerian patients with sickle cell anaemia. PLoS ONE, 2018, 13, e0197927.	1.1	18
42	Genetic control of erythropoiesis. Current Opinion in Hematology, 2017, 24, 173-182.	1.2	10
43	Sickle cell disease in the older adult. Pathology, 2017, 49, 1-9.	0.3	48
44	Association of plasma CD40L with acute chest syndrome in sickle cell anemia. Cytokine, 2017, 97, 104-107.	1.4	23
45	Associations between environmental factors and hospital admissions for sickle cell disease. Haematologica, 2017, 102, 666-675.	1.7	29
46	A Plea for the Newborn Diagnosis of Hb S-Hereditary Persistence of Fetal Hemoglobin. Hemoglobin, 2017, 41, 216-217.	0.4	7
47	Detection of Hb Rothschild HBB: c.[112T>A or 112T>C], Through High Index of Suspicion on Abnormal Pulse Oximetry. Hemoglobin, 2017, 41, 137-139.	0.4	6
48	Genetic Basis and Genetic Modifiers of Î²-Thalassemia and Sickle Cell Disease. Advances in Experimental Medicine and Biology, 2017, 1013, 27-57.	0.8	33
49	Increased prevalence of renal cysts in patients with sickle cell disease. BMC Nephrology, 2017, 18, 298.	0.8	8
50	Reduced rate of sickleâ€related complications in Brazilian patients carrying HbFâ€promoting alleles at the BCL11A and HMIPâ€2 loci. British Journal of Haematology, 2016, 173, 456-460.	1.2	25
51	Genetic Factors Modifying Sickle Cell Disease Severity. , 2016, , 371-397.		3
52	Survival in adults with sickle cell disease in a high-income setting. Blood, 2016, 128, 1436-1438.	0.6	153
53	Loss of Major DNase I Hypersensitive Sites in DuplicatedÎ²-globinGene Cluster Incompletely SilencesHBBGene Expression. Human Mutation, 2016, 37, 1153-1156.	1.1	6
54	<scp>ASH</scp>1L (a histone methyltransferase protein) is a novel candidate globin gene regulator revealed by genetic study of an English family with betaâ€thalassaemia unlinked to the betaâ€globin locus. British Journal of Haematology, 2016, 175, 525-530.	1.2	6

#	Article	IF	Citations
55	Intracranial Aneurysms in Sickle-Cell Disease Are Associated With the Hemoglobin SS Genotype But Not With Moyamoya Syndrome. Stroke, 2016, 47, 1710-1713.	1.0	27
56	Airway and alveolar nitric oxide production, lung function, and pulmonary blood flow in sickle cell disease. Pediatric Research, 2016, 79, 313-317.	1.1	11
57	The investigation of resveratrol and analogs as potential inducers of fetal hemoglobin. Blood Cells, Molecules, and Diseases, 2016, 58, 6-12.	0.6	16
58	Genetic variants at HbFâ€modifier loci moderate anemia and leukocytosis in sickle cell disease in T anzania. American Journal of Hematology, 2015, 90, E1-4.	2.0	21
59	The clinical significance of K-Cl cotransport activity in red cells of patients with HbSC disease. Haematologica, 2015, 100, 595-600.	1.7	18
60	Prevention of Morbidity in sickle cell disease - qualitative outcomes, pain and quality of life in a randomised cross-over pilot trial of overnight supplementary oxygen and auto-adjusting continuous positive airways pressure (POMS2a): study protocol for a randomised controlled trial. Trials, 2015, 16, 376.	0.7	10
61	Superâ€elevated <scp>LDH</scp> and thrombocytopenia are markers of a severe subtype of vasoâ€occlusive crisis in sickle cell disease. American Journal of Hematology, 2015, 90, E206-7.	2.0	13
62	Response to hydroxyurea among <scp>K</scp>uwaiti patients with sickle cell disease and elevated baseline <scp>H</scp>b<scp>F</scp> levels. American Journal of Hematology, 2015, 90, E138-9.	2.0	15
63	First reported duplication of the entire beta globin gene cluster causing an unusual sickle cell trait phenotype. British Journal of Haematology, 2015, 170, 128-131.	1.2	8
64	Spectral domain optical coherence tomography in patients with sickle cell disease. British Journal of Ophthalmology, 2015, 99, 967-972.	2.1	74
65	Genetic association of fetal-hemoglobin levels in individuals with sickle cell disease in Tanzania maps to conserved regulatory elements within the MYB core enhancer. BMC Medical Genetics, 2015, 16, 4.	2.1	24
66	Genome-wide association analyses based on whole-genome sequencing in Sardinia provide insights into regulation of hemoglobin levels. Nature Genetics, 2015, 47, 1264-1271.	9.4	66
67	Next Generation Sequencing Identifies a Novel Rearrangement in theHBBCluster Permitting to-the-Base Characterization. Human Mutation, 2015, 36, 142-150.	1.1	20
68	Pulmonary Haemodynamics in Sickle Cell Disease Are Driven Predominantly by a High-Output State Rather Than Elevated Pulmonary Vascular Resistance: A Prospective 3-Dimensional Echocardiography/Doppler Study. PLoS ONE, 2015, 10, e0135472.	1.1	24
69	Genome Wide Association Study of Fetal Hemoglobin in Sickle Cell Anemia in Tanzania. PLoS ONE, 2014, 9, e111464.	1.1	78
70	Anemia in the elderly: clinical implications and new therapeutic concepts. Haematologica, 2014, 99, 1127-1130.	1.7	62
71	Global Genetic Architecture of an Erythroid Quantitative Trait Locus,HMIP-2. Annals of Human Genetics, 2014, 78, 434-451.	0.3	24
72	Pulmonary function, CT and echocardiographic abnormalities in sickle cell disease. Thorax, 2014, 69, 746-751.	2.7	31

#	Article	IF	Citations
73	HBS1L-MYB intergenic variants modulate fetal hemoglobin via long-range MYB enhancers. Journal of Clinical Investigation, 2014, 124, 1699-1710.	3.9	157
74	How we treat sickle hepatopathy and liver transplantation in adults. Blood, 2014, 123, 2302-2307.	0.6	71
75	How I treat renal complications in sickle cell disease. Blood, 2014, 123, 3720-3726.	0.6	62
76	Genetic association studies in Î²-hemoglobinopathies. Hematology American Society of Hematology Education Program, 2013, 2013, 354-361.	0.9	62
77	The Molecular Basis of Â-Thalassemia. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a011700-a011700.	2.9	268
78	<scp>H</scp>b<scp>A</scp>₂ levels in normal adults are influenced by two distinct genetic mechanisms. British Journal of Haematology, 2013, 160, 101-105.	1.2	32
79	Genetic determinants of haemolysis in sickle cell anaemia. British Journal of Haematology, 2013, 161, 270-278.	1.2	45
80	The effect of Duffy antigen receptor for chemokines on severity in sickle cell disease. Haematologica, 2013, 98, e87-e89.	1.7	12
81	Safety and Tolerability Of MP4CO: A Dose Escalation Study In Stable Patients With Sickle Cell Disease. Blood, 2013, 122, 2205-2205.	0.6	25
82	Super-Elevated LDH and Thombocytopenia Are Markers Of An Unusual Sickle Phenomenon. Blood, 2013, 122, 2220-2220.	0.6	0
83	HBS1L-MYB intergenic Variants Modulate Fetal Hemoglobin Via Long-Range MYB Enhancers. Blood, 2013, 122, 43-43.	0.6	1
84	Telomere Lengths Correlate With Inflammatory Markers In Sickle Cell Disease. Blood, 2013, 122, 2230-2230.	0.6	0
85	Association between hemolysis and albuminuria in adults with sickle cell anemia. Haematologica, 2012, 97, 201-205.	1.7	97
86	Serum ferritin and total units transfused for assessing iron overload in adults with sickle cell disease. British Journal of Haematology, 2012, 157, 645-647.	1.2	20
87	European Chromosome 6 Haplotypes Significantly Augment Fetal Hemoglobin Levels in Brazilian Sickle Cell Anemia Patients: Influence of Four HBS1L-MYB Intergenic Region SNPs. Blood, 2012, 120, 1002-1002.	0.6	0
88	Genetic Modifiers of Sickle Cell Disease. Hemoglobin, 2011, 35, 589-606.	0.4	24
89	Genetics of fetal hemoglobin in Tanzanian and British patients with sickle cell anemia. Blood, 2011, 117, 1390-1392.	0.6	104
90	Blood transfusion usage among adults with sickle cell disease â€“ a single institution experience over ten years. British Journal of Haematology, 2011, 152, 766-770.	1.2	53

#	Article	IF	Citations
91	Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nature Genetics, 2011, 43, 295-301.	9.4	142
92	Two Distinct Genetic Mechanisms Modify the Level of HbA2 in Peripheral Blood,. Blood, 2011, 118, 3193-3193.	0.6	0
93	Renal Iron Load in Sickle Cell Disease Correlates with Hemolysis and Transfusion History, but Not with Hepatic Iron. Blood, 2011, 118, 2129-2129.	0.6	0
94	Acute human parvovirus B19 infection and nephrotic syndrome in patients with sickle cell disease. British Journal of Haematology, 2010, 149, 289-291.	1.2	10
95	Binding patterns of BCL11A in the globin and GATA1 loci and characterization of the BCL11A fetal hemoglobin locus. Blood Cells, Molecules, and Diseases, 2010, 45, 140-146.	0.6	52
96	Addition of Hydroxyurea to Transfusion Programme to Treat Progressive Cerebral Vasculopathy. Blood, 2010, 116, 4813-4813.	0.6	0
97	The Molecular Basis of Î² Thalassemia, ÎÎ² Thalassemia, and Hereditary Persistence of Fetal Hemoglobin. , 2009, , 323-356.		34
98	Association of sickle avascular necrosis with bone morphogenic protein 6. Annals of Hematology, 2009, 88, 803-805.	0.8	25
99	Discovering the genetics underlying foetal haemoglobin production in adults. British Journal of Haematology, 2009, 145, 455-467.	1.2	171
100	A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nature Genetics, 2009, 41, 1182-1190.	9.4	481
101	Control of fetal hemoglobin: new insights emerging from genomics and clinical implications. Human Molecular Genetics, 2009, 18, R216-R223.	1.4	213
102	The HBS1L-MYB intergenic interval associated with elevated HbF levels shows characteristics of a distal regulatory region in erythroid cells. Blood, 2009, 114, 1254-1262.	0.6	95
103	Extracranial Internal Carotid Arterial Disease in Children with Sickle Cell Disease.. Blood, 2009, 114, 2560-2560.	0.6	0
104	Hydroxyurea therapy lowers circulating DNA levels in sickle cell anemia. American Journal of Hematology, 2008, 83, 714-716.	2.0	18
105	Genetic modifiers of the Î²â€haemoglobinopathies. British Journal of Haematology, 2008, 141, 357-366.	1.2	117
106	The presence of Î±â€thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease. British Journal of Haematology, 2008, 143, 589-592.	1.2	19
107	Sickle cell disease in a carrier with pyruvate kinase deficiency. Hematology, 2008, 13, 369-372.	0.7	15
108	Deferasirox Efficacy and Safety for the Treatment of Transfusion- Dependent Iron Overload in Patients with a Range of Rare Anemias.. Blood, 2008, 112, 1419-1419.	0.6	2

#	Article	IF	Citations
109	Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 11346-11351.	3.3	286
110	The HBS1L-MYB intergenic region on chromosome 6q23.3 influences erythrocyte, platelet, and monocyte counts in humans. Blood, 2007, 110, 3624-3626.	0.6	71
111	Hepatic Dysfunction in Sickle Cell Disease: A New System of Classification Based on Global Assessment. Clinical Gastroenterology and Hepatology, 2007, 5, 1469-1476.	2.4	79
112	A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nature Genetics, 2007, 39, 1197-1199.	9.4	491
113	Molecular therapies in ?-thalassaemia. British Journal of Haematology, 2007, 136, 353-365.	1.2	83
114	The linear effects ofÎ±-thalassaemia, theUGT1A1andHMOX1polymorphisms on cholelithiasis in sickle cell disease. British Journal of Haematology, 2007, 138, 263-270.	1.2	77
115	Circulating DNA: a potential marker of sickle cell crisis. British Journal of Haematology, 2007, 139, 331-336.	1.2	19
116	cMYB is involved in the regulation of fetal hemoglobin production in adults. Blood, 2006, 108, 1077-1083.	0.6	163
117	Sickle Cell Anaemia in East Africa: Preliminary Results from a Cohort Study.. Blood, 2006, 108, 3802-3802.	0.6	3
118	Cell Free Fetal and Total DNA Levels in Pregnancies at Risk of Sickle Cell Disease and Significant Ethnic Variation.. Blood, 2006, 108, 3791-3791.	0.6	0
119	Pathophysiology of Î² Thalassemiaâ€"A Guide to Molecular Therapies. Hematology American Society of Hematology Education Program, 2005, 2005, 31-37.	0.9	76
120	Heterogeneity of the ÎµÎ³ÎΒ Thalassemias: Characterization of 3 Novel English Deletions.. Blood, 2004, 104, 3609-3609.	0.6	0
121	Automated genotyping for accurate assignment of the (AT)x Nz (AT)y motif within the Î²-globin locus control region-hypersensitive site 2. British Journal of Haematology, 2001, 112, 488-492.	1.2	3
122	IS IT DOMINANTLY INHERITED Î² THALASSAEMIA OR JUST A Î²-CHAIN VARIANT THAT IS HIGHLY UNSTABLE?. British Journal of Haematology, 1999, 107, 12-21.	1.2	60
123	An in vitro system for expression analysis of mutations of the Î²-globin gene: validation and application to two mutations in the 5â€² UTR. British Journal of Haematology, 1999, 106, 938-947.	1.2	18
124	Elimination of Transfusions Through Induction of Fetal Hemoglobin Synthesis in Cooley's Anemiaa. Annals of the New York Academy of Sciences, 1998, 850, 100-109.	1.8	47
125	Recombination Breakpoints in the Human Î²-Globin Gene Cluster. Blood, 1998, 92, 4415-4421.	0.6	64
126	Erythroblastic Inclusions in Dominantly Inherited Î² Thalassemias. Blood, 1997, 89, 322-328.	0.6	45

#	Article	IF	Citations
127	Prenatal Diagnosis in Combined Antithrombin and Factor V Gene Mutation. British Journal of Haematology, 1996, 94, 753-755.	1.2	7
128	A base substitution (Tâ†'C) in codon 29 of the Î±2â€globin gene causes Î± thalassaemia. British Journal of Haematology, 1993, 85, 546-552.	1.2	47
129	The spectrum of Î² thalassaemia in Burma. British Journal of Haematology, 1992, 81, 574-578.	1.2	14
130	Molecular characterization of a novel 10.3 kb deletion causing Î²â€thalassaemia with unusually high Hb A₂. British Journal of Haematology, 1992, 82, 735-744.	1.2	48
131	DOMINANT Î² THALASSAEMIA: MOLECULAR BASIS AND PATHOPHYSIOLOGY. British Journal of Haematology, 1992, 80, 273-277.	1.2	89
132	Hypervariable â€˜minisatelliteâ€™ regions in human DNA. Nature, 1985, 314, 67-73.	13.7	3,495